
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Professor Laure Gossec is Professor of Rheumatology in Sorbonne Université and Pitié-Salpêtrière Hospital, Paris, France. Professor Gossec has a half-time clinical position where she mainly sees patients with inflammatory arthritis, and a half-time teaching and research position.
Professor Gossec earned her medical degree and conducted her specialty training in rheumatology at Paris Descartes University, France, and earned her PhD in clinical epidemiology from Montpellier University, France. Professor Gossec’s clinical research focuses on particular outcomes research and epidemiological research, with a focus on outcome measures, prediction of outcome and targeted treatments, in psoriatic arthritis (PsA), rheumatoid arthritis (RA) and spondyloarthritis. Professor Gossec is particularly interested in the patient’s perspective and patient-centred research, and e-health and artificial intelligence for rheumatology research.
In 2023, Professor Gossec has coordinated work on quality of life in spondyloarthritis in several databases, she was the methodologist for a European Alliance of Associations of Rheumatology (EULAR) Task Force on patient involvement in research (led by Dr de Wit, Netherlands) and she co-led a EULAR Task Force with Professor Smolen (Austria) to produce an update of the EULAR recommendations for the management of PsA.
Professor Gossec is past Chair of the Epidemiology standing committee of EULAR and is a founding member and past Chair of the Emerging EULAR Network (EMEUNET). She is an Associate Editor for Joint Bone Spine.
Professor Gossec has authored more than 450 peer-reviewed manuscripts published in journals such as Annals of the Rheumatic Diseases, Arthritis & Rheumatology, Rheumatology and Arthritis Research and Therapy.
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.
Watch Prof Robert Landewé discuss the importance of using ASDAS <2.1 as a treatment target for patients with axSpA.
Read our key takeaways from the 2022 ASAS-EULAR recommendations for the management of axSpA, presented as part of Dr Sofia Ramiro's workshop at UCB Summit 2023.